A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing

•There is a need for robust biomarkers for MS diagnosis and prognosis.•Point-of-care testing (POCT) provides quick results via handheld or bench-top devices.•Biosensors are important tools that can be adapted to POCT of patients with MS.•There are examples of biosensors developed to detect certain b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis and related disorders 2021-02, Vol.48, p.102675-102675, Article 102675
1. Verfasser: Can Demirdöğen, Birsen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 102675
container_issue
container_start_page 102675
container_title Multiple sclerosis and related disorders
container_volume 48
creator Can Demirdöğen, Birsen
description •There is a need for robust biomarkers for MS diagnosis and prognosis.•Point-of-care testing (POCT) provides quick results via handheld or bench-top devices.•Biosensors are important tools that can be adapted to POCT of patients with MS.•There are examples of biosensors developed to detect certain biomarkers of MS.•Nanomaterials and artificial intelligence add to the improvement of biosensors. Multiple sclerosis (MS) is a chronic neuroinflammatory disease of the central nervous system that leads to severe motor and sensory deficits in patients. Although some biomolecules in serum or cerebrospinal fluid have been suggested as biomarkers for MS diagnosis, following disease activity and monitoring treatment response, most of these potential biomarkers are not currently in clinical use and available for all patients. The reasons behind this are generally related to insufficient robustness of biomarker or technical difficulties, high prices, and requirements for technical personnel for their detection. Point-of-care testing (POCT) is an emerging field of healthcare that can be applied at the hospital as well as at home without the need for a centralized laboratory. Biosensor devices offer a convenient means for POCT. A biosensor is a compact analytical device that uses a bioreceptor, such as an antibody, enzyme, or oligonucleotide, to capture the analyte of interest. The interaction between the analyte and the bioreceptor is sensed and transduced into a suitable signal by the signal transducer. The advantages of using a biosensor for detecting the biomolecule of interest include speed, simplicity, accuracy, relatively lower cost, and lack of requirements for highly qualified personnel to perform the testing. Owing to these advantages and with the help of innovations in biosensor development technologies, there has been a great interest in developing biosensor devices for MS in recent years. Hence, the purpose of this review was to provide researchers with an up-to-date summary of the literature as well as to highlight the challenges and opportunities in this translational research field. In addition, because this is a highly interdisciplinary field of study, potentially concerning MS specialists, neurologists, biomedical researchers, and engineers, another aim of this review was to bridge the gap between these disciplines.
doi_str_mv 10.1016/j.msard.2020.102675
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2470897260</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2211034820307495</els_id><sourcerecordid>2470897260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-4fa3c6ef0fd14a589b02157cb3d8888f5c95ff4d3b8d29f96117e7c492ef88f03</originalsourceid><addsrcrecordid>eNp9kE9P3DAQxS1UxKItnwAJ-dhLFv9JnKRSDwi1UAmpFzhbjj1GXiVx1pMUlU9fLwt7ZC62xm_m-f0IueRswxlX19vNgCa5jWBi3xGqrk7IuRCcF0xW6svxXjYrcoG4ZblUxUvFz8hKSilUy-pzsruhfZghmXlJQBP8DfBCo6ddiAgjxoTUx0SHpZ_D1ANF20OKGPA7fYwv-QdIJ0gYR9OHV3B0ABdsGIGa0dEphnEuoi-syctnwDmMz1_JqTc9wsX7uSZPv34-3t4XD3_uft_ePBRWVu1clN5Iq8Az73hpqqbtmOBVbTvpmly-sm3lfelk1zjR-lZxXkNty1aAz89Mrsm3w94pxd2SvfUQ0ELfmxHiglqUNWvaWqi9VB6kNkfDBF5PKQwm_dOc6T1uvdVvuPUetz7gzlNX7wZLl2MfZz7gZsGPgwByzAw2abQBRpsRJbCzdjF8avAfxJ2Tng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2470897260</pqid></control><display><type>article</type><title>A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Can Demirdöğen, Birsen</creator><creatorcontrib>Can Demirdöğen, Birsen</creatorcontrib><description>•There is a need for robust biomarkers for MS diagnosis and prognosis.•Point-of-care testing (POCT) provides quick results via handheld or bench-top devices.•Biosensors are important tools that can be adapted to POCT of patients with MS.•There are examples of biosensors developed to detect certain biomarkers of MS.•Nanomaterials and artificial intelligence add to the improvement of biosensors. Multiple sclerosis (MS) is a chronic neuroinflammatory disease of the central nervous system that leads to severe motor and sensory deficits in patients. Although some biomolecules in serum or cerebrospinal fluid have been suggested as biomarkers for MS diagnosis, following disease activity and monitoring treatment response, most of these potential biomarkers are not currently in clinical use and available for all patients. The reasons behind this are generally related to insufficient robustness of biomarker or technical difficulties, high prices, and requirements for technical personnel for their detection. Point-of-care testing (POCT) is an emerging field of healthcare that can be applied at the hospital as well as at home without the need for a centralized laboratory. Biosensor devices offer a convenient means for POCT. A biosensor is a compact analytical device that uses a bioreceptor, such as an antibody, enzyme, or oligonucleotide, to capture the analyte of interest. The interaction between the analyte and the bioreceptor is sensed and transduced into a suitable signal by the signal transducer. The advantages of using a biosensor for detecting the biomolecule of interest include speed, simplicity, accuracy, relatively lower cost, and lack of requirements for highly qualified personnel to perform the testing. Owing to these advantages and with the help of innovations in biosensor development technologies, there has been a great interest in developing biosensor devices for MS in recent years. Hence, the purpose of this review was to provide researchers with an up-to-date summary of the literature as well as to highlight the challenges and opportunities in this translational research field. In addition, because this is a highly interdisciplinary field of study, potentially concerning MS specialists, neurologists, biomedical researchers, and engineers, another aim of this review was to bridge the gap between these disciplines.</description><identifier>ISSN: 2211-0348</identifier><identifier>EISSN: 2211-0356</identifier><identifier>DOI: 10.1016/j.msard.2020.102675</identifier><identifier>PMID: 33326907</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Biomarker ; Biomarkers ; Biosensing Techniques ; Humans ; Immunosensor ; Lab-on-a-chip ; Microfluidic ; Multiple Sclerosis - diagnosis ; Nanomaterial ; Nanoparticle ; Patient-centered healthcare ; Personalized medicine ; Point-of-Care Testing ; Precision Medicine</subject><ispartof>Multiple sclerosis and related disorders, 2021-02, Vol.48, p.102675-102675, Article 102675</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-4fa3c6ef0fd14a589b02157cb3d8888f5c95ff4d3b8d29f96117e7c492ef88f03</citedby><cites>FETCH-LOGICAL-c359t-4fa3c6ef0fd14a589b02157cb3d8888f5c95ff4d3b8d29f96117e7c492ef88f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33326907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Can Demirdöğen, Birsen</creatorcontrib><title>A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing</title><title>Multiple sclerosis and related disorders</title><addtitle>Mult Scler Relat Disord</addtitle><description>•There is a need for robust biomarkers for MS diagnosis and prognosis.•Point-of-care testing (POCT) provides quick results via handheld or bench-top devices.•Biosensors are important tools that can be adapted to POCT of patients with MS.•There are examples of biosensors developed to detect certain biomarkers of MS.•Nanomaterials and artificial intelligence add to the improvement of biosensors. Multiple sclerosis (MS) is a chronic neuroinflammatory disease of the central nervous system that leads to severe motor and sensory deficits in patients. Although some biomolecules in serum or cerebrospinal fluid have been suggested as biomarkers for MS diagnosis, following disease activity and monitoring treatment response, most of these potential biomarkers are not currently in clinical use and available for all patients. The reasons behind this are generally related to insufficient robustness of biomarker or technical difficulties, high prices, and requirements for technical personnel for their detection. Point-of-care testing (POCT) is an emerging field of healthcare that can be applied at the hospital as well as at home without the need for a centralized laboratory. Biosensor devices offer a convenient means for POCT. A biosensor is a compact analytical device that uses a bioreceptor, such as an antibody, enzyme, or oligonucleotide, to capture the analyte of interest. The interaction between the analyte and the bioreceptor is sensed and transduced into a suitable signal by the signal transducer. The advantages of using a biosensor for detecting the biomolecule of interest include speed, simplicity, accuracy, relatively lower cost, and lack of requirements for highly qualified personnel to perform the testing. Owing to these advantages and with the help of innovations in biosensor development technologies, there has been a great interest in developing biosensor devices for MS in recent years. Hence, the purpose of this review was to provide researchers with an up-to-date summary of the literature as well as to highlight the challenges and opportunities in this translational research field. In addition, because this is a highly interdisciplinary field of study, potentially concerning MS specialists, neurologists, biomedical researchers, and engineers, another aim of this review was to bridge the gap between these disciplines.</description><subject>Biomarker</subject><subject>Biomarkers</subject><subject>Biosensing Techniques</subject><subject>Humans</subject><subject>Immunosensor</subject><subject>Lab-on-a-chip</subject><subject>Microfluidic</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Nanomaterial</subject><subject>Nanoparticle</subject><subject>Patient-centered healthcare</subject><subject>Personalized medicine</subject><subject>Point-of-Care Testing</subject><subject>Precision Medicine</subject><issn>2211-0348</issn><issn>2211-0356</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9P3DAQxS1UxKItnwAJ-dhLFv9JnKRSDwi1UAmpFzhbjj1GXiVx1pMUlU9fLwt7ZC62xm_m-f0IueRswxlX19vNgCa5jWBi3xGqrk7IuRCcF0xW6svxXjYrcoG4ZblUxUvFz8hKSilUy-pzsruhfZghmXlJQBP8DfBCo6ddiAgjxoTUx0SHpZ_D1ANF20OKGPA7fYwv-QdIJ0gYR9OHV3B0ABdsGIGa0dEphnEuoi-syctnwDmMz1_JqTc9wsX7uSZPv34-3t4XD3_uft_ePBRWVu1clN5Iq8Az73hpqqbtmOBVbTvpmly-sm3lfelk1zjR-lZxXkNty1aAz89Mrsm3w94pxd2SvfUQ0ELfmxHiglqUNWvaWqi9VB6kNkfDBF5PKQwm_dOc6T1uvdVvuPUetz7gzlNX7wZLl2MfZz7gZsGPgwByzAw2abQBRpsRJbCzdjF8avAfxJ2Tng</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Can Demirdöğen, Birsen</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202102</creationdate><title>A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing</title><author>Can Demirdöğen, Birsen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-4fa3c6ef0fd14a589b02157cb3d8888f5c95ff4d3b8d29f96117e7c492ef88f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarker</topic><topic>Biomarkers</topic><topic>Biosensing Techniques</topic><topic>Humans</topic><topic>Immunosensor</topic><topic>Lab-on-a-chip</topic><topic>Microfluidic</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Nanomaterial</topic><topic>Nanoparticle</topic><topic>Patient-centered healthcare</topic><topic>Personalized medicine</topic><topic>Point-of-Care Testing</topic><topic>Precision Medicine</topic><toplevel>online_resources</toplevel><creatorcontrib>Can Demirdöğen, Birsen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis and related disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Can Demirdöğen, Birsen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing</atitle><jtitle>Multiple sclerosis and related disorders</jtitle><addtitle>Mult Scler Relat Disord</addtitle><date>2021-02</date><risdate>2021</risdate><volume>48</volume><spage>102675</spage><epage>102675</epage><pages>102675-102675</pages><artnum>102675</artnum><issn>2211-0348</issn><eissn>2211-0356</eissn><abstract>•There is a need for robust biomarkers for MS diagnosis and prognosis.•Point-of-care testing (POCT) provides quick results via handheld or bench-top devices.•Biosensors are important tools that can be adapted to POCT of patients with MS.•There are examples of biosensors developed to detect certain biomarkers of MS.•Nanomaterials and artificial intelligence add to the improvement of biosensors. Multiple sclerosis (MS) is a chronic neuroinflammatory disease of the central nervous system that leads to severe motor and sensory deficits in patients. Although some biomolecules in serum or cerebrospinal fluid have been suggested as biomarkers for MS diagnosis, following disease activity and monitoring treatment response, most of these potential biomarkers are not currently in clinical use and available for all patients. The reasons behind this are generally related to insufficient robustness of biomarker or technical difficulties, high prices, and requirements for technical personnel for their detection. Point-of-care testing (POCT) is an emerging field of healthcare that can be applied at the hospital as well as at home without the need for a centralized laboratory. Biosensor devices offer a convenient means for POCT. A biosensor is a compact analytical device that uses a bioreceptor, such as an antibody, enzyme, or oligonucleotide, to capture the analyte of interest. The interaction between the analyte and the bioreceptor is sensed and transduced into a suitable signal by the signal transducer. The advantages of using a biosensor for detecting the biomolecule of interest include speed, simplicity, accuracy, relatively lower cost, and lack of requirements for highly qualified personnel to perform the testing. Owing to these advantages and with the help of innovations in biosensor development technologies, there has been a great interest in developing biosensor devices for MS in recent years. Hence, the purpose of this review was to provide researchers with an up-to-date summary of the literature as well as to highlight the challenges and opportunities in this translational research field. In addition, because this is a highly interdisciplinary field of study, potentially concerning MS specialists, neurologists, biomedical researchers, and engineers, another aim of this review was to bridge the gap between these disciplines.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33326907</pmid><doi>10.1016/j.msard.2020.102675</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2211-0348
ispartof Multiple sclerosis and related disorders, 2021-02, Vol.48, p.102675-102675, Article 102675
issn 2211-0348
2211-0356
language eng
recordid cdi_proquest_miscellaneous_2470897260
source MEDLINE; Alma/SFX Local Collection
subjects Biomarker
Biomarkers
Biosensing Techniques
Humans
Immunosensor
Lab-on-a-chip
Microfluidic
Multiple Sclerosis - diagnosis
Nanomaterial
Nanoparticle
Patient-centered healthcare
Personalized medicine
Point-of-Care Testing
Precision Medicine
title A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A22%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20literature%20review%20of%20biosensors%20for%20multiple%20sclerosis:%20Towards%20personalized%20medicine%20and%20point-of-care%20testing&rft.jtitle=Multiple%20sclerosis%20and%20related%20disorders&rft.au=Can%20Demird%C3%B6%C4%9Fen,%20Birsen&rft.date=2021-02&rft.volume=48&rft.spage=102675&rft.epage=102675&rft.pages=102675-102675&rft.artnum=102675&rft.issn=2211-0348&rft.eissn=2211-0356&rft_id=info:doi/10.1016/j.msard.2020.102675&rft_dat=%3Cproquest_cross%3E2470897260%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2470897260&rft_id=info:pmid/33326907&rft_els_id=S2211034820307495&rfr_iscdi=true